Approval · Notice of Compliance 22351 · 2019
ZOFRAN: Notice of Compliance 22351
Issued July 2, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22351
- Date
- July 2, 2019
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a drug substance manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZOFRAN | Not yet assigned | — |
Medicinal ingredients
- ONDANSETRON HYDROCHLORIDE DIHYDRATE 4 MG per TAB
- ONDANSETRON HYDROCHLORIDE DIHYDRATE 8 MG per TAB
- ONDANSETRON HYDROCHLORIDE DIHYDRATE 2 MG per ML